GlassScriptPhysician profile
Christina Cullison
NPI 1831761287
$9,167.50
in general payments reported to CMS, 2019-2025
31 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,016 · 2023: $2,378 · 2024: $3,091 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,151.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,526.20 | 2022-2025 | |
| Janssen Biotech, INC. | $1,699.54 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $829.64 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $546.28 | 2024-2025 | Voquezna |
| Genzyme Corporation | $460.81 | 2022-2025 | |
| Gilead Sciences, INC. | $436.76 | 2023-2025 | Epclusa, Livdelzi |
| Janssen Scientific Affairs, LLC | $347.32 | 2023-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.46 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $270.76 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $228.76 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $212.25 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $183.72 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $178.93 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $164.57 | 2023-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $118.62 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $106.67 | 2024-2025 | |
| Organon LLC | $66.42 | 2023-2024 | Hadlima |
| Intercept Pharmaceuticals, INC. | $58.20 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $45.53 | 2024 | Iqirvo, Bylvay |
| Celgene Corporation | $43.65 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $41.42 | 2022-2024 | Dificid, Zinplava |
| Braintree Laboratories, INC. | $40.79 | 2022-2023 | Suflave, Sutab |
| Dynavax Technologies Corporation | $36.78 | 2023 | Heplisav-B |
| Exact Sciences Corporation | $34.93 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $29.19 | 2022 | |
| Madrigal Pharmaceuticals | $26.48 | 2024 | Resmetirom |
| Boston Scientific Corporation | $25.40 | 2024 | Watchman Flx |
| Nestle Healthcare Nutrition INC. | $19.40 | 2023 | |
| Digestive Care, INC. | $17.92 | 2024 | Pertzye |
| Shield Therapeutics INC | $15.14 | 2022 | |
| Daiichi Sankyo INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Cullison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.